Plasmapheresis procedure was assessed by Spanish Health Technology Assessment Agency (AETS) in patients with Alzheimer’s disease

Feb 2018

In December, 2017 the Spanish Health Technology Assessment Agency (AETS) published report with results of evaluation of plasmapheresis use in patients with Alzheimer’s disease.

Efficacy and safety of procedure was assessed within systematic literature review. Only three studies with significant methodological limitations were identified. Thus, available evidence was assessed as very low with a high risk of bias. Furthermore, data from clinical studies did not report quantitative efficacy and safety results which were inconclusive.

Therefore, AETS stated that available evidence is not sufficient to give final conclusion for recommendations of application of plasmapheresis in patients with Alzheimer’s disease.

See list of report in Spanish here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

Rapid HTAs of five medical devices released in Tuscany

Mar 2022

The HTA body of the Tuscany Regional Healthcare issues two types of documents: HTA forms and motivational forms. With a regional decree 2472 of February 10, 2022, Tuscany Regional Healthcare has published assessments of five medical devices of various therapeutic areas, such as cardiovascular and peripheral vascular areas.

Draft Order amending the Common Package of Benefits of the Spanish National Health System

Mar 2022

On February 21, 2022, it was announced by the Ministry of Health that the public consultation regarding the Draft Order amending the Common Package of Benefits of the National Health System (SNS) was open. The amendments and clarifications are related to the fields of in-vitro diagnostics, ENT, pulmonary and airways, e-health, neurology, dental care, radiology, and enteral nutrition.

Belgian KCE developing procedure for assessment of digital health technologies

Mar 2022

The Belgian Health Care Knowledge Center (KCE) initiated a study aimed at defining a clear and transparent procedure for the evaluation of digital health technologies in Belgium.

Assessments of monitoring and diagnostics of atrial fibrillation products released in Sweden

Mar 2022

On February 07, 2022, the Dental and Pharmaceutical Benefits Agency has announced the withdrawal of the assessments of the PhysioMem PM 100 and CardioMem CM 100 XT and the finalization of the assessments of the Zenicor ECG, Coala Heart Monitor Pro, and KardiaMobile. For the conducted assessments, it was outlined that the portable devices provide more limited information than standard ECG measurements; therefore, it was mainly estimated for atrial fibrillation.

HTAs published by FinCCHTA in February 2022

Mar 2022

In February 2022, the Finnish Coordinating Center for Health Technology Assessment announced the release of the seven accomplished rapid hospital assessments performed by the Helsinki, Tampere, and Oulu University Hospital. The accomplished rapid HTAs concern the diagnostic imaging, e-Health, endocrine, endoscopy, men’s health, neuromodulation technology groups.